As of 2024-12-14, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (17.64) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.95 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -353.7%.
The range of the Relative Valuation is (18.27) - (18.62) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.8x - 24.1x | 17.3x |
| Forward P/E multiples | 18.8x - 19.2x | 19.0x |
| Fair Price | (18.27) - (18.62) | (17.64) |
| Upside | -362.8% - -367.9% | -353.7% |
| Date | P/E |
| 2024-12-06 | -8.24 |
| 2024-12-05 | -6.78 |
| 2024-12-04 | -7.34 |
| 2024-12-03 | -7.30 |
| 2024-12-02 | -7.80 |
| 2024-11-29 | -7.28 |
| 2024-11-27 | -6.57 |
| 2024-11-26 | -6.06 |
| 2024-11-25 | -6.18 |
| 2024-11-22 | -5.87 |
| 2024-11-21 | -5.92 |
| 2024-11-20 | -6.22 |
| 2024-11-19 | -6.45 |
| 2024-11-18 | -6.28 |
| 2024-11-15 | -6.36 |
| 2024-11-14 | -7.11 |
| 2024-11-13 | -7.53 |
| 2024-11-12 | -7.80 |
| 2024-11-11 | -8.07 |
| 2024-11-08 | -7.31 |
| 2024-11-07 | -7.13 |
| 2024-11-06 | -7.17 |
| 2024-11-05 | -7.02 |
| 2024-11-04 | -6.83 |
| 2024-11-01 | -6.59 |
| 2024-10-31 | -6.50 |
| 2024-10-30 | -6.88 |
| 2024-10-29 | -6.94 |
| 2024-10-28 | -7.07 |
| 2024-10-25 | -6.67 |
| 2024-10-24 | -6.55 |
| 2024-10-23 | -6.51 |
| 2024-10-22 | -6.80 |
| 2024-10-21 | -6.96 |
| 2024-10-18 | -7.14 |
| 2024-10-17 | -6.74 |
| 2024-10-16 | -7.21 |
| 2024-10-15 | -6.86 |
| 2024-10-14 | -6.92 |
| 2024-10-11 | -6.81 |
| 2024-10-10 | -6.36 |
| 2024-10-09 | -6.33 |
| 2024-10-08 | -6.63 |
| 2024-10-07 | -6.36 |
| 2024-10-04 | -6.29 |
| 2024-10-03 | -6.24 |
| 2024-10-02 | -6.29 |
| 2024-10-01 | -6.35 |
| 2024-09-30 | -6.78 |
| 2024-09-27 | -7.18 |